admin – Page 2931 – Get News Story

Liver Fibrosis Market Forecast to 2034: Evolving Therapeutic Strategies Amid Rising Disease Burden | DelveInsight

“Liver fibrosis is a progressive condition caused by chronic liver injury from diseases like NASH, hepatitis B/C, alcohol-related liver disease, and autoimmune hepatitis. If untreated, it can lead to cirrhosis, liver failure, or hepatocellular carcinoma (HCC), yet often goes undiagnosed early due to its silent progression.”

Liver fibrosis is a progressive condition caused by chronic liver injury from diseases like NASH, hepatitis B/C, alcohol-related liver disease, and autoimmune hepatitis. If untreated, it can lead to cirrhosis, liver failure, or hepatocellular carcinoma (HCC), yet often goes undiagnosed early due to its silent progression.

DelveInsight’s latest report, “Liver Fibrosis – Market Insight, Epidemiology, and Market Forecast – 2034,” delivers a detailed analysis of the disease landscape across the 7MM (the US, EU4 [Germany, France, Italy, Spain], the UK, and Japan). The report provides granular epidemiological segmentation based on fibrosis staging (F0–F4), etiology, and diagnostic modality. It highlights shifting trends in liver disease etiology, such as the rising incidence of NASH-related fibrosis, particularly in aging and metabolically at-risk populations.

The liver fibrosis market is entering a transformative phase, driven by greater awareness, improved diagnostic tools—including non-invasive imaging and serum biomarkers—and a rapidly advancing therapeutic pipeline. While current management largely focuses on treating the underlying cause of liver injury, emerging therapies aim to directly halt or reverse fibrogenesis. Notably, the approval of REZDIFFRA (resmetirom) in the US for MASH has set the stage for the introduction of more antifibrotic agents.

Looking ahead, the liver fibrosis treatment market is expected to expand significantly by 2034, supported by the launch of first-in-class agents, growing screening initiatives, and investment in fibrosis-specific R&D. DelveInsight’s comprehensive report outlines market dynamics, late-stage pipeline assets, unmet needs, and strategic insights for stakeholders navigating this high-potential therapeutic space.

Request a sample and uncover the latest breakthroughs shaping the Liver Fibrosis market landscape and future outlook

Some of the key insights of the Liver Fibrosis Market Report:

• In 2023, the liver fibrosis market in the 7MM was valued at USD 1.8 billion, projected to grow at a ~24% CAGR through 2034.

• The U.S. liver fibrosis market was USD 1.3 billion in 2023, expected to grow with upcoming therapies.

• There were ~8 million diagnosed prevalent cases in the 7MM in 2023.

• The U.S. accounted for 51.4% of cases, EU4 and the UK for 34.1%, and Japan for 14.4%.

• The U.S. had the highest burden, with ~4 million cases in 2023, expected to rise by 2034.

• In May 2025, Novo Nordisk announced that it will present new data from its portfolio in metabolic and cardiovascular health at the 32nd European Congress on Obesity (ECO) from May 11–14, 2025. The data will include real-world evidence studies on semaglutide, additional analysis of the SELECT cardiovascular outcomes trial, and part 1 of the phase III ESSENCE trial for metabolic dysfunction-associated steatohepatitis (MASH).

• In May 2025, Roche announced the launch of its ELECSYS PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Developed in collaboration with Nordic Bioscience, the test provides clinicians with a simple and efficient way to identify patients with liver fibrosis of varying severity, facilitating timely intervention and management of the disease.

• In November 2024, Novo Nordisk announced positive results for semaglutide in treating metabolic dysfunction-associated steatohepatitis (MASH). In the Phase III Essence trial, a once-weekly 2.4 mg dose of semaglutide improved liver fibrosis and resolved steatohepatitis without worsening liver fibrosis in MASH patients with stage 2 or stage 3 fibrosis, meeting the primary endpoints.

• Emerging therapies for liver fibrosis include Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Lanifibranor (IVA337), Aramchol, WEGOVY (semaglutide 2.4 mg), VK2809 (TRß Agonist), Rencofilstat (CRV431), Ervogastat + Clesacostat, Berberine ursodeoxycholate (HTD1801), Efimosfermin alfa, HU6, LPCN 1144, ALG-055009, MN-001 (tipelukast), Icosabutate, Tirzepatide (LY3298176), and others.

• Key companies involved in the treatment of liver fibrosis include Inventiva Pharma, Galmed Research and Development, Ltd., Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, Axcella Therapeutics, Akero Therapeutics, Inc., Lipocine Inc., Enyo Pharma, Sagimet Biosciences Inc., 89bio Inc., HighTide Biopharma, Rivus Pharmaceuticals Inc., Novo Nordisk A/S, and others.

Curious to see the graphical version of these numbers? The liver fibrosis infographic is ready for you. Check it out here!

Liver Fibrosis Overview

Liver Fibrosis is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial Liver Fibrosis is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers.

The most common and aggressive subtype is High-Grade Serous Liver Fibrosis (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Liver Fibrosis (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection.

Over the past decade, the Liver Fibrosis treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control.

As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development.

Liver Fibrosis Epidemiology

The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.

Liver Fibrosis Epidemiology Segmentation:

The Liver Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:

• Total Liver Fibrosis Diagnosed Prevalent Cases

• Liver Fibrosis Severity-specific Diagnosed Prevalent Cases

• Total Liver Fibrosis Diagnosed Prevalent Cases (≥F2 Stage) in MASH

Liver Fibrosis Drugs Uptake and Pipeline Development Activities

The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Liver Fibrosis throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Liver Fibrosis drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Liver Fibrosis, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Liver Fibrosis therapeutics.

Get a free sample for the liver fibrosis market forecast, size & share analysis report: https://www.delveinsight.com/report-store/liver-fibrosis-market

Liver Fibrosis Market Outlook

The liver fibrosis treatment landscape is undergoing significant transformation, with increased focus on targeted therapies aimed at addressing the underlying fibrotic processes rather than just the causative liver diseases. The approval of REZDIFFRA (resmetirom) by the US FDA for noncirrhotic NASH with moderate to advanced fibrosis marks a major milestone, offering both hepatic fat reduction and fibrogenic pathway modulation.

Despite progress, the Liver Fibrosis market continues to face substantial unmet needs. Currently available treatments primarily slow progression, but cannot reverse established fibrosis. This gap highlights the urgent demand for anti-fibrotic agents, regenerative therapies, and advanced non-invasive biomarkers to improve early detection and therapeutic monitoring.

Several Liver Fibrosis therapies are under clinical development, focusing on metabolic reprogramming, inflammation reduction, and fibrosis regression. Notable candidates include GLP-1/glucagon receptor agonists like Survodutide, FGF21 analogs Pegozafermin and Efruxifermin, and PPAR agonists such as Lanifibranor. Other approaches, like RNA interference (Fazirsiran), lipid synthesis inhibitors (Denifanstat, Aramchol), and cyclophilin inhibitors (Rencofilstat), represent diverse mechanisms targeting the complex fibrotic cascade.

Key Liver Fibrosis companies leading innovation include Inventiva Pharma, Galmed Pharmaceuticals, Novo Nordisk, and others. A rich pipeline featuring drugs such as HU6, LPCN 1144, MN-001, Icosabutate, Lixudebart, PHIN-214, and FXR314 underscores the growing momentum in this therapeutic area.

With rising disease prevalence, evolving diagnostics, and a promising therapeutic pipeline, the Liver Fibrosis market is expected to witness strong growth and innovation through 2034.

Liver Fibrosis Market Drivers

• The increasing global burden of non-alcoholic steatohepatitis (NASH), metabolic syndrome, and obesity is contributing to a surge in liver fibrosis cases, especially in developed countries.

• Recent FDA approval of REZDIFFRA (resmetirom) and a robust pipeline of novel agents (targeting fibrosis pathways, lipid metabolism, and inflammation) are driving growth and attracting investment in the Liver Fibrosis treatment landscape.

Liver Fibrosis Market Barriers

• Current therapies primarily slow progression but do not reverse fibrosis, highlighting a critical unmet need in delivering effective anti-fibrotic solutions.

• The absence of reliable, non-invasive diagnostic tools and standardized biomarkers hampers early detection and monitoring, making it challenging to track therapeutic response and patient stratification.

Scope of the Liver Fibrosis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].

• Key Liver Fibrosis Companies: Inventiva Pharma, Galmed Research and Development, Ltd., Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, Axcella Therapeutics, Akero Therapeutics, Lipocine Inc., Enyo Pharma, Sagimet Biosciences Inc., 89bio Inc., HighTide Biopharma, Rivus Pharmaceuticals Inc., Novo Nordisk A/S, and others.

• Key Liver Fibrosis Therapies: Efruxifermin (EFX), Denifanstat (TVB-2640), Survodutide (BI 456906), Pegozafermin (BIO89-100), Lanifibranor (IVA337), Aramchol, WEGOVY (semaglutide 2.4 mg), VK2809 (TRß Agonist), Rencofilstat (CRV431), Ervogastat + Clesacostat, Berberine ursodeoxycholate (HTD1801), Efimosfermin alfa, HU6, LPCN 1144, ALG-055009, MN-001 (tipelukast), Icosabutate, Tirzepatide (LY3298176), and others.

• Liver Fibrosis Therapeutic Assessment: Liver Fibrosis currently marketed, and Liver Fibrosis emerging therapies.

• Liver Fibrosis Market Dynamics: Liver Fibrosis market drivers and Liver Fibrosis market barriers.

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies.

• Liver Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Liver Fibrosis Market Access and Reimbursement.

To learn more about Liver Fibrosis companies working in the treatment market, check out our Liver Fibrosis Market Report

Table of Contents

1. Liver Fibrosis Market Report Introduction

2. Executive Summary for Liver Fibrosis

3. SWOT analysis of Liver Fibrosis

4. Liver Fibrosis Patient Share (%) Overview at a Glance

5. Liver Fibrosis Market Overview at a Glance

6. Liver Fibrosis Disease Background and Overview

7. Liver Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Fibrosis

9. Liver Fibrosis Current Treatment and Medical Practices

10. Liver Fibrosis Unmet Needs

11. Liver Fibrosis Emerging Therapies

12. Liver Fibrosis Market Outlook

13. Country-Wise Liver Fibrosis Market Analysis (2020–2034)

14. Liver Fibrosis Market Access and Reimbursement of Therapies

15. Liver Fibrosis Market Drivers

16. Liver Fibrosis Market Barriers

17. Liver Fibrosis Appendix

18. Liver Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Liver Fibrosis Market Forecast to 2034: Evolving Therapeutic Strategies Amid Rising Disease Burden | DelveInsight

Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “Vitiligo Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

To know in detail about the Vitiligo market outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Vitiligo Treatment Market Size

Key Takeaways from the Vitiligo Market Report

In June 2025, Incyte Corporation announced a study to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with non-segmental vitiligo.
In June 2025, Pfizer conducted a study to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of non-segmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body, such as both knees and both hands.
In June 2025, Vyne Therapeutics Inc. organized a Phase 2b Trial Evaluating the Efficacy, Safety & Pharmacokinetics of VYN201 Gel in the Treatment of Non-Segmental Vitiligo.
According to the findings, the United States accounted for around 60% of the Vitiligo diagnosed Prevalent Cases in the 7MM in 2023.
In EU4 and the UK, Germany contributed the highest patient share of vitiligo, followed by the UK. Whereas Spain contributed to the lowest patient share.
As per the estimates, there were 493,000 treated cases of vitiligo in the 7MM in 2023.
The leading Vitiligo Companies such as Incyte, AbbVie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others
Promising Vitiligo Pipeline Therapies such as OPZELURA (ruxolitinib cream), RINVOQ (upadacitinib), Ritlecitinib, Afamelanotide, Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, and others.

Get a Free sample for the Vitiligo Therapeutics Market Report @ Vitiligo Drugs Market

Vitiligo Epidemiology Segmentation in the 7MM

Vitiligo Prevalence Cases
Vitiligo Type-specific Cases
Vitiligo Diagnosed Prevalent Cases
Vitiligo Treated Cases

Download the report to understand which factors are driving Vitiligo epidemiology trends @ Vitiligo Prevalence

Vitiligo Marketed Drugs

OPZELURA (ruxolitinib cream): Incyte

In July 2024, the US FDA approved a groundbreaking treatment for vitiligo, a chronic immune-mediated skin disorder characterized by depigmented white patches on the skin. The newly approved drug, OPZELURA, is a topical Janus kinase (JAK) inhibitor called ruxolitinib. This approval marks a significant milestone, as OPZELURA is the first FDA-approved pharmacologic treatment specifically designed to address repigmentation in vitiligo patients, particularly those with nonsegmental vitiligo, the most common form of the condition. OPZELURA works by targeting JAK1 and JAK2 receptors to decrease interferon gamma signaling by immune cells, thereby halting the destruction of melanocytes responsible for skin color.

Vitiligo Emerging Drugs

RINVOQ (upadacitinib): Abbvie

Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated to treat alopecia areata, ankylosing spondylitis, atopic dermatitis, axial SpA, Crohn’s disease, giant cell arteritis, hidradenitis suppurativa (HS), psoriatic arthritis, rheumatoid arthritis, systemic lupus erthematosus (SLE), Takayasu arteritis, ulcerative colitis, and vitiligo. Currently, the drug is in Phase III for the treatment of vitiligo, for which primary completion date is December 2024. At the 2024 AAD Annual Meeting, late-breaking data showed that upadacitinib demonstrated clinically meaningful repigmentation of extensive vitiligo after 52 weeks, potentially offering a new and effective systemic treatment for non-segmental vitiligo.

LITFULO (Ritlecitinib): Pfizer

LITFULO (ritlecitinib) is considered a kinase inhibitor, meaning it prevents kinases, which are certain proteins in the immune system, from working properly. This in turn blocks the immune pathways that are thought to contribute to the development of autoimmune diseases, resulting in symptom improvements, such as repigmentation or stopping of disease progression in vitiligo. Currently, there is a Phase III Vitiligo Clinical Trial underway with an estimated completion date in June 2025. Depending on the results of that trial, ritlecitinib may be approved for vitiligo treatment.

Discover more about therapies set to grab major Vitiligo market share @ Vitiligo Clinical Trials Assessment

Vitiligo Treatment Market

The Vitiligo Treatment Market Landscape is undergoing rapid transformation, marked by significant advancements anticipated in 2024 and beyond. With the introduction of FDA-approved topical therapies and the emergence of oral JAK inhibitors, dermatology is experiencing remarkable progress in managing this complex condition. These developments signify a promising future for vitiligo patients, reflecting the evolving strategies aimed at enhancing treatment efficacy and patient outcomes. Key Vitiligo Companies such as AbbVie, Incyte, Pfizer, and others are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of vitiligo. Vitiligo treatment typically involves a combination approach, incorporating various topical therapies such as steroids, vitamin D analogues, and calcineurin inhibitors. While mono-therapy topicals have shown improvement, the most effective treatment strategy often involves a combination of phototherapy, oral antioxidants, and both oral and topical medications. This multifaceted approach addresses the complex nature of vitiligo and maximizes therapeutic outcomes. Driven by rising awareness and new treatment options, the vitiligo market is poised for steady growth in the coming years.

Vitiligo Drugs and Companies

OPZELURA (ruxolitinib cream): Incyte
RINVOQ (upadacitinib): AbbVie
Ritlecitinib: Pfizer
Afamelanotide: Clinuvel, Inc.
Phimelanotide – Clinuvel Pharmaceuticals
BNZ-1: Bioniz Therapeutics
TAGX-0003: TAGCyx Biotechnologies
TT-01: Temprian Therapeutics
ATI-1777: Aclaris Therapeutics
AC-1101: TWi Biotechnology
Cerdulatinib: Dermavant Sciences
AMG 714: Amgen
Ritlecitinib: Pfizer
Ruxolitinib: Incyte Corporation

Vitiligo Market Drivers

Increasing awareness
Demand for novel therapies
Large patient pool and better healthcare infrastructure

Vitiligo Market Barriers

Patient compliance
Chronic nature of the disease and long-term therapy
Lack of adequate financial assistance & stringent regulatory procedure

Download DelveInsight’s latest report to gain strategic insights into upcoming Vitiligo Therapies and key Vitiligo Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives

Scope of the Vitiligo Market Report

Coverage- 7MM
Study Period- 2020-2034
Vitiligo Companies- Incyte, AbbVie, Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotechnologies, Temprian Therapeutics, Aclaris Therapeutics, TWi Biotechnology, Dermavant Sciences, Amgen, Pfizer, Incyte Corporation, and others
Vitiligo Pipeline Therapies- OPZELURA (ruxolitinib cream), RINVOQ (upadacitinib), Ritlecitinib, Afamelanotide, Phimelanotide, BNZ-1, TAGX-0003, TT-01, ATI-1777, AC-1101, Cerdulatinib, AMG 714, Ritlecitinib, Ruxolitinib, and others.
Vitiligo Therapeutic Assessment: Vitiligo current marketed and emerging therapies
Vitiligo Market Dynamics: Vitiligo market drivers and Vitiligo market barriers
Vitiligo Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Vitiligo Unmet Needs, KOL’s views, Analyst’s views, Vitiligo Market Access and Reimbursement

Table of Contents

1 Key Insights

2 Vitiligo Market Report Introduction

3 Vitiligo Executive Summary

4 Key Events

5 Vitiligo Epidemiology and Market Forecast Methodology

6 Vitiligo Market Overview at a Glance

7 Disease Background and Overview: Vitiligo

8 Vitiligo Treatment and Management

9 Vitiligo Epidemiology and Patient Population in the 7MM

10 Patient Journey

11 Vitiligo Marketed Therapies

12 Vitiligo Emerging Therapies

13 Vitiligo: Seven Major Market Analysis

14 Vitiligo Unmet Needs

15 Vitiligo SWOT Analysis

16 Vitiligo KOL Views

17 Vitiligo Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/vitiligo-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vitiligo Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Systemic Lupus Erythematosus Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

DelveInsight’s “Systemic Lupus Erythematosus Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

To know in detail about the Systemic Lupus Erythematosus Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Systemic Lupus Erythematosus Treatment Market Size

Key Takeaways from the Systemic Lupus Erythematosus Market Report

In June 2025, UCB Biopharma SRL announced a study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
In June 2025, Novartis Pharmaceuticals conducted a study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
In June 2025, AstraZeneca conducted a study to evaluate the efficacy and safety of a subcutaneous treatment regimen of anifrolumab versus placebo in participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment. Participants must be taking either 1 or any combination of the following: oral glucocorticoids, antimalarial, and/or immunosuppressants. The study will be performed in adult participants of 18 to 70 years of age.
In June 2025, Merck Sharp & Dohme LLC organized a study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
In June 2025, AbbVie organized a study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.
Between EU4 and the UK, Spain accounted for the highest number of Systemic Lupus Erythematosus Diagnosed Prevalent Cases followed by the UK and Germany.
The age group most affected by the systemic lupus erythematosus prevalence is 40-59 years. In 2023, among 7MM, approximately 40% of cases belonged to the 40-59 years age group.
In 2023, approximately 50% of cases were found to be moderate cases in Spain.
The leading Systemic Lupus Erythematosus Companies such as Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie and others.
Promising Systemic Lupus Erythematosus Pipeline Therapies such as Obexelimab, Telitacicept, DS-7011a, Belimumab (GSK1550188), Sirolimus, Ianalumab, ALPN-101, BMS-986165, JMKX000189, BMS-986165 and others.

Get a Free sample for the Systemic Lupus Erythematosus Therapeutics Market Report @ Systemic Lupus Erythematosus Drugs Market

Systemic Lupus Erythematosus Epidemiology Segmentation in the 7MM

Total Diagnosed Prevalent Cases
Total Diagnosed Prevalent Cases by Gender
Total Diagnosed Prevalent Cases by Age
Severity-Based Diagnosed Prevalent Cases
Total Treated Cases

Download the report to understand which factors are driving Systemic Lupus Erythematosus Epidemiology trends @ Systemic Lupus Erythematosus Prevalence

Systemic Lupus Erythematosus Marketed Drugs

BENLYSTA (belimumab): GlaxoSmithKline

BENLYSTA (belimumab), a B-lymphocyte stimulator (BLyS) specific inhibitor, is a fully human monoclonal antibody that binds to soluble BLyS, which is found to be increased in patients with systemic autoimmune diseases like SLE and lupus nephritis (LN). ABy bding BLyS, BENLYSTA inhibits the prolonged survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. BENLYSTA does not bind B cells directly. The US FDA first approved BENLYSTA for the treatment of active systemic lupus erythematosus; it is the first and only approved biologic for both SLE and LN in more than 50 years, including for the pediatric population. It was first approved by the US FDA in 2011.

SAPHNELO (anifrolumab): AstraZeneca

SAPHNELO (anifrolumab) is a first in class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity. SAPHNELO is approved to treat systemic lupus erythematosus in more than 60 countries worldwide including the US, EU and Japan, with reviews ongoing in other countries.

Systemic Lupus Erythematosus Emerging Drugs

Cenerimod: Idorsia Pharmaceuticals/Viatris

Cenerimod is a highly selective sphingosine-1-phosphate receptor 1 (S1P1) receptor modulator, given as an oral once-daily tablet. While the cause of SLE is not fully known, T and B-lymphocytes are considered the key immune cells playing a role in the development of SLE. T and B-lymphocytes have a cell surface receptor called S1P1. These receptors enable T and B-lymphocytes to detect the signaling molecule S1P – sphingosine 1 phosphate – which is responsible for lymphocyte trafficking from the lymph nodes to the circulation. By binding to S1P1 receptors, a receptor modulator can trigger the internalization of those receptors. This effectively blinds T and B lymphocytes to the S1P gradient, thereby holding them in the lymph nodes and reducing autoreactive T and B cells in the circulation and, consequently, also in the tissues. In December 2017, the US FDA designated the investigation of cenerimod for the treatment of SLE as a fast-track development program. Currently it is in Phase III of its clinical development.

Litifilimab: Biogen

Litifilimab is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of SLE and cutaneous lupus erythematosus (CLE). BDCA2 is a receptor that is predominantly expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs). The binding of litifilimab to BDCA2 has been shown to reduce the production of pro-inflammatory molecules by pDCs, including type-I interferon (IFN-I) as well as other cytokines and chemokines. Currently it is in Phase III of its clinical development.

Discover more about therapies set to grab major Systemic Lupus Erythematosus Drugs Market Share @ Systemic Lupus Erythematosus Clinical Trials Assessment

Systemic Lupus Erythematosus Treatment Market

Systemic lupus erythematosus is a chronic autoimmune disease that can affect many parts of the body. Lupus occurs when the immune system, which normally helps protect the body from infection and disease, attacks its own tissues. This attack causes inflammation, and in some cases permanent tissue damage, which can be widespread – affecting the skin, joints, heart, lung, kidneys, circulating blood cells, and brain. The systemic lupus erythematosus diagnosis is based on a combination of clinical findings and laboratory evidence. Familiarity with the diagnostic criteria helps clinicians to recognize systemic lupus erythematosus and to subclassify this complex disease based on the pattern of target-organ manifestations. The ACR/EULAR classification requires an antinuclear antibody (ANA) titer of at least 1:80 on HEp-2 cells or an equivalent positive test at least once. If that is present, 22 “additive weighted” classification criteria are considered, comprising seven clinical domains (constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and three immunologic domains (antiphospholipid antibodies, complement proteins, SLE-specific antibodies). Each criterion is assigned points, ranging from 2 to 10. Patients with at least one clinical criterion and 10 or more points are classified as having systemic lupus erythematosus.

Scope of the Systemic Lupus Erythematosus Market Report

Coverage- 7MM
Study Period- 2020-2034
Systemic Lupus Erythematosus Companies- Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie and others.
Systemic Lupus Erythematosus Pipeline Therapies- Obexelimab, Telitacicept, DS-7011a, Belimumab (GSK1550188), Sirolimus, Ianalumab, ALPN-101, BMS-986165, JMKX000189, BMS-986165 and others.
Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and emerging therapies
Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers
Systemic Lupus Erythematosus Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Systemic Lupus Erythematosus Unmet Needs, KOL’s views, Analyst’s views, Systemic Lupus Erythematosus Market Access and Reimbursement

Download DelveInsight’s latest report to gain strategic insights into upcoming Systemic Lupus Erythematosus Therapies and Drugs Developments @ Systemic Lupus Erythematosus Market Drivers and Barriers, and Future Perspectives

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Systemic Lupus Erythematosus

4. Epidemiology and Market Forecast Methodology

5. SLE Market Overview at a Glance

6. Systemic Lupus Erythematosus Market Disease Background and Overview

7. Systemic Lupus Erythematosus Epidemiology and Patient Population

8. Systemic Lupus Erythematosus Marketed Therapies

9. Systemic Lupus Erythematosus Emerging Therapies

10. Systemic Lupus Erythematosus (SLE): The 7MM Analysis

11. Systemic Lupus Erythematosus Unmet Needs

12. Systemic Lupus Erythematosus SWOT Analysis

13. Systemic Lupus Erythematosus KOL Views

14. Systemic Lupus Erythematosus Market Access and Reimbursement

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Lupus Erythematosus Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight

Uveitis Treatment Market Size in the 7MM was ~USD 1,468.66 million in 2022 and is expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Uveitis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of uveitis, historical and forecasted epidemiology, as well as the uveitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Uveitis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Uveitis Market Forecast. Click here to stay ahead in healthcare innovation @ Uveitis Market Size

Key Takeaways from the Uveitis Market Report

In June 2025, AbbVie announced a study is to assess adverse events and effectiveness of adalimumab in Chinese participants requiring high-dose corticosteroids with NIIPPU. Adalimumab is a conditionally approved drug in China used to treat participants with NIIPPU. All participants will receive the same treatment. Approximately 87 adult participants will be enrolled at approximately 15 sites in China.
As per DelveInsight analysis, in 2022, there were approximately 1,009,025 Uveitis diagnosed prevalent cases in the 7MM.
The total number of Uveitis diagnosed prevalent cases in the US was around 378,281 in 2022.
The US contributed to the largest Uveitis diagnosed prevalent population, acquiring ~37.5% of the 7MM in 2022. Whereas Spain accounted for the least, with around ~7% of the total population share, respectively, in 2022.
In the US, patients diagnosed with noninfectious uveitis (NIU) are higher in number than infectious uveitis (IU). In 2022, there were nearly 344,587 cases of NIU, while IU accounted for around 33,695 cases. These numbers are expected to rise during the forecast period due to the rise of overall uveitis infection in the US.
According to DelveInsight estimates, in EU4 and the UK, based on anatomical location highest cases of uveitis were diagnosed in anterior uveitis, while intermediate uveitis has the least cases. In EU4 and the UK, anterior uveitis accounted for approximately 203,439, followed by 84,154 cases in posterior uveitis, 81,773 cases in pan uveitis, and 46,485 in intermediate uveitis in 2022, which are projected to increase during the forecast period.
Japan accounted for approximately 214,892 diagnosed prevalent cases of uveitis, out of which nearly 8,039 cases were of HLA-B27-associated uveitis, 17,315 sarcoidosis, 9,894 Behçet’s disease, 8,658 Vogt–Koyanagi–Harada disease, 618 JIA, 309 ankylosing spondylitis, 3,092 tuberculosis, 11,749 herpes, 81,628 idiopathic, and 73,589 others cases in 2022. These uveitis cases are expected to change during the forecast period in Japan (2023–2034).
The leading Uveitis Companies such as AbbVie Inc., Novartis AG, Allergan Inc., Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd, Eyegate Pharmaceuticals Inc., Regeneron Pharmaceuticals, Eyepoint pharmaceuticals Inc., Alimera Sciences Inc., and others.
Promising Uveitis Therapies such as Brepocitinib 45 mg PO QD, Izokibep, QLETLI, Baricitinib, Adalimumab, and others.

Navigate the complexities of the Uveitis Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Uveitis Market Forecast. Click here to get more insights @ Uveitis Treatment Market

Uveitis Epidemiology Segmentation in the 7MM

• Total Diagnosed Prevalent Cases

• Type-specific Diagnosed Prevalent Cases

• Diagnosed Prevalent Cases of Uveitis by Anatomical

• Etiology-specific Diagnosed Prevalent Cases

Delve deep into the Uveitis Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Uveitis Market Forecast. Click here to shape the future @ Uveitis Prevalence

Uveitis Marketed Drugs

XIPERE: Clearside Biomedical/Bausch+Lomb

XIPERE, a triamcinolone acetonide injectable suspension, is the first approved medicine delivery via injection for suprachoroidal use to treat macular edema associated with uveitis in the US. Delivering the medicine to the suprachoroidal space (SCS) allows targeted delivery of the therapy with low levels elsewhere in the eye.

YUTIQ/ILUVIEN: EyePoint Pharmaceuticals/Alimera Sciences

YUTIQ is a sterile nonbioerodible intravitreal implant with 0.18 mg fluocinolone acetonide. It releases the drug at an initial rate of 0.25 µg/day in a 36-month sustained-release drug delivery system. YUTIQ contains a corticosteroid and is indicated for treating chronic noninfectious uveitis affecting the posterior segment of the eye. It is preloaded into a single-dose applicator to facilitate the injection of the implant directly into the vitreous. It was approved by the US FDA in October 2018 and launched commercially in February 2019.

Uveitis Emerging Drugs

TRS01: Tarsier Pharma

TRS01, a lead product of Tarsier Pharmaceuticals, first in first-in-class topical immune modulator agent. Dazdotuftide (TRS) is a breakthrough platform technology for treating blinding ocular diseases. TRS was developed to ‘re-engineer’ the immune system. The platform approaches inflammatory diseases from within the system. The technology can effectively treat various autoimmune and inflammatory ocular diseases. TRS01 is a polypeptide conjugate with a dual mechanism of action; the investigational agent induces anti-inflammatory macrophages and inhibits the nuclear factor-kB (Nf-kB) signaling pathway by toll-like receptor 4 (TLR4).

OCS-02 (licaminlimab): Oculis Pharma

OCS-02 (licaminlimab) is a single-chain antibody fragment (scFv) that binds to and neutralizes the activity of human TNFa, with a dual mechanism of action (MoA), anti-inflammation, and anti-necrosis. Unlike full-length monoclonal antibodies, scFv fragments can penetrate ocular surface tissues when used as eye drops due to the smaller molecule size giving it the potential to become the first approved topical biologic for DED (dry eye disease) (OCS-02 was previously known as LME636).

Unlock insights into the Uveitis Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Uveitis Market Forecast. Click here @ Uveitis Market Drivers and Barriers

Uveitis Drugs Market Insights

A severe intraocular inflammatory condition of the uveal tract known as uveitis frequently results in vision loss, blindness, and reduced quality of life. With the disease having a variable presentation, diagnosis and management are difficult. Treatment aims at obtaining quiescence of the disease, either by treating the infectious agent or treating the immune condition. The current promising pharmacological classes for uveitis treatment include corticosteroids, immunosuppressants, and biologics. The uveitis drugs market is growing, driven by innovative therapies and increasing global prevalence.

Uveitis Therapies and Companies

• TRS01: Tarsier Pharma

• Licaminlimab (OCS-02): Oculis Pharma

• Vamikibart (RO720220/RG6179): Roche/Eleven Biotherapeutics

• OLUMIANT (baricitinib): Eli Lilly and Company

• EYS606: Eyevensys

• Izokibep: Acelyrin/Affibody Medical

• Brepocitinib: Priovant Therapeutics (Roivant Sciences and Pfizer)

Uveitis Market Outlook

Uveitis is a serious intraocular inflammatory disorder of the uveal tract, often associated with visual impairment, blindness, and decreased quality of life. It often affects patients in their most active and economically productive years. It is the leading cause of preventable blindness worldwide and is a critically underserved disease in terms of treatment. With the disease having a variable presentation, diagnosis and management are difficult. A prompt diagnosis, with the correct diagnostic approach and assessment of appropriate treatment, is extremely important to reduce inflammation and attain complete remission, thereby mitigating or avoiding ocular complications, permanent cumulative damage, and long-term vision loss. Treatment aims at obtaining quiescence of the disease, either by treating the infectious agent or treating the immune condition.

Gain a strategic edge in the Uveitis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Uveitis Market Forecast. Click here to lead in advancements @ Uveitis Clinical Trials Assessment

Scope of the Uveitis Market Report

• Coverage- 7MM

• Uveitis Companies- AbbVie Inc., Novartis AG, Allergan Inc., Bausch & Lomb Incorporated, Santen Pharmaceutical Co., Ltd, Eyegate Pharmaceuticals Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences Inc., and others.

• Uveitis Therapies- Brepocitinib 45 mg PO QD, Izokibep, QLETLI, Baricitinib, Adalimumab, and others.

• Uveitis Market Dynamics: Uveitis Market Drivers and Uveitis Market Barriers

• Uveitis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Uveitis Unmet Needs, KOL’s views, Analyst’s views, Uveitis Market Access and Reimbursement

Table of Contents

1. Key Insights

2. Report Introduction

3. Uveitis Market Overview at a Glance

4. Methodology of Uveitis Epidemiology and Market

5. Executive Summary of Uveitis

6. Key Events

7. Disease Background and Overview of Uveitis

8. Patient Journey

9. Epidemiology and Patient Population

10. Marketed Drugs

11. Emerging Drugs

12. Uveitis: Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Uveitis Treatment Market Size in the 7MM was ~USD 1,468.66 million in 2022 and is expected to increase by 2034, estimates DelveInsight

Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts | DelveInsight

“Ovarian Cancer Market”

Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection.

DelveInsight’s latest report, “Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,” provides a comprehensive overview of the disease’s burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation.

The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress.

Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight’s full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients.

Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook

Some of the key insights of the Ovarian Cancer Market Report:

• In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion.

• Market size is expected to grow with the launch of new ovarian cancer therapies.

• The U.S. held the largest share, reaching USD 1.92 billion in 2024.

• Total incident ovarian cancer cases in the 7MM were 61K in 2024.

• The U.S. reported the highest number of high and low-grade serous ovarian cancer cases.

• There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024.

• In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model.

• In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer.

• In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer.

• Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others.

• Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others.

Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here!

Ovarian Cancer Overview

Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers.

The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection.

Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control.

Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: https://www.delveinsight.com/sample-request/ovarian-cancer-market

Ovarian Cancer Epidemiology

Ovarian Cancer Epidemiology Segmentation:

The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:

• Total incident cases of Ovarian Cancer

• Age-specific cases of Ovarian Cancer

• Type-Specific Cases of Ovarian Cancer

• Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer

• Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer

Ovarian Cancer Drugs Uptake and Pipeline Development Activities

The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments.

The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction.

Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics.

Ovarian Cancer Market Outlook

The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival.

The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment.

However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial.

The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements.

Ovarian Cancer Market Drivers

• The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups.

• Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options.

Ovarian Cancer Market Barriers

• The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes.

• Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis.

Scope of the Ovarian Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].

• Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others.

• Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others.

• Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies.

• Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers.

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies.

• Ovarian Cancer Unmet Needs, KOL’s views, Analyst’s views, Ovarian Cancer Market Access and Reimbursement.

To learn more about Ovarian Cancer companies working in the treatment market, check out our Ovarian Cancer Market Report

Table of Contents

1. Ovarian Cancer Market Report Introduction

2. Executive Summary for Ovarian Cancer

3. SWOT analysis of Ovarian Cancer

4. Ovarian Cancer Patient Share (%) Overview at a Glance

5. Ovarian Cancer Market Overview at a Glance

6. Ovarian Cancer Disease Background and Overview

7. Ovarian Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Ovarian Cancer

9. Ovarian Cancer Current Treatment and Medical Practices

10. Ovarian Cancer Unmet Needs

11. Ovarian Cancer Emerging Therapies

12. Ovarian Cancer Market Outlook

13. Country-Wise Ovarian Cancer Market Analysis (2020–2034)

14. Ovarian Cancer Market Access and Reimbursement of Therapies

15. Ovarian Cancer Market Drivers

16. Ovarian Cancer Market Barriers

17. Ovarian Cancer Appendix

18. Ovarian Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts | DelveInsight

Credit Risk Assessment Market Global Rising Demand & Huge Scope Till 2032 | Coherent Market Insights

“Credit Risk Assessment Market”

Market Size and Overview

Market Size and Overview- The Global Credit Risk Assessment Market size is estimated to be valued at USD 9.52 Bn in 2025 (market size) and is expected to reach USD 23.97 Bn by 2032 (market forecast), exhibiting a compound annual growth rate (CAGR) of 14.1% from 2025 to 2032. This forecast underscores strong adoption across banking, insurance and corporate finance sectors, supported by evolving market dynamics and rising demand for predictive credit scoring.

Industry Overview

The credit evaluation domain is witnessing accelerated digitization as financial institutions and fintechs deploy advanced analytics and AI-driven models for real-time decision-making. Robust risk governance frameworks and regulatory mandates are driving demand for end-to-end credit risk assessment platforms. Our proprietary market research and market insights reveal a dynamic landscape where legacy systems are being replaced by cloud-native architectures, setting the stage for significant business growth.

Request Sample Pages: https://www.coherentmarketinsights.com/insight/request-sample/6486

Key Takeaways

Region

• North America: Early adopters of AI-powered scoring engines, driven by stringent regulatory environments.

• Latin America: Growth fueled by microfinance expansions in Brazil and Mexico.

• Europe: GDPR-compliant risk solutions prompting upgrades in Western Europe.

• Asia Pacific: Rapid digitization in India and Southeast Asia accelerating demand.

• Middle East: Infrastructure financing units in UAE and Saudi Arabia integrating advanced analytics.

• Africa: Emerging markets leveraging mobile-driven credit models for unbanked populations.

Segment Covers

• Component:

– Solutions (Credit Scoring, Portfolio Management, Fraud Detection): Example use case—real-time score recalibration in major lenders.

– Services (Consulting, Integration, Support): Example use case—end-to-end deployment with 24/7 support for regional banks.

• Deployment:

– Cloud: Scalable scoring platforms launched by global fintechs.

– On-Premise: Mission-critical systems preferred by tier-1 banks for data sovereignty.

• End-User Industry:

– Banking & Finance: 45% of deals in 2024 for retail and corporate credit risk.

– Telecom & Retail: Use cases include postpaid billing risk and supplier credit profiling.

Growth Factors

• Rising Non-Performing Loans (NPLs): NPL ratios climbed to 4.8% in global banking portfolios in 2024, spurring demand for automated risk monitoring (market drivers).

• AI/ML Integration: Adoption of machine learning algorithms grew 28% year-on-year in 2024, enhancing predictive accuracy (industry size).

• Regulatory Pressure: Basel III and IFRS 9 compliance programs accounted for 35% of new license revenues (Credit Risk Assessment Market revenue).

Get Customization on this Report: https://www.coherentmarketinsights.com/insight/request-customization/6486

Market Trends

• Real-Time Risk Monitoring: Over 60% of new deployments in 2025 offer continuous score updates (Credit Risk Assessment Market share).

• Open Banking APIs: Data sharing initiatives led to a 22% rise in third-party risk data utilization (market trends).

• Explainable AI: Transparency requirements driving investment in model interpretability frameworks, with 18% more R&D projects in 2024 (industry trends).

Actionable Insights

Supply-Side Indicators

• New Solution Releases: Grew from 150 in 2024 to 210 in 2025, boosting overall production capacity by 40%.

• Average License Pricing: Increased by 8% in 2024 as vendors bundled AI modules (market scope).

• Export Penetration: APAC exports accounted for 30% of total software shipments in 2024.

Demand-Side Indicators

• Imports: Financial institutions in Latin America imported 45% of their risk platforms in 2024.

• Use Cases Across Industries: BFSI accounted for 50% of new subscriptions, telecom 15%, retail 10%.

• Nano-Indicators: Average daily risk checks per client rose from 2.1 million to 3.4 million in 2024 (market dynamics).

Key Players

• Experian

• Equifax

• TransUnion

• FICO

• Moody’s Analytics

• Oracle

• IBM

• SAP

• SAS Institute

• Fiserv

• Pegasystems

• Genpact

• ACL

• Kroll

• PRMIA

• Riskonnect

• RiskSpotter

• Riskdata

• BRASS

• Misys

Competitive Strategies

• Experian’s 2024 acquisition of an AI-analytics startup drove a 15% uptick in Credit Risk Assessment Market report revenues.

• FICO launched a cloud-native scoring service in Q3 2024, boosting its market share by 5% in North America.

• Oracle partnered with leading regional banks in Asia Pacific for embedded risk modules, resulting in a 20% increase in subscription renewals.

Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6486

FAQs

1. Who are the dominant players in the Credit Risk Assessment Market?

Dominant players include Experian, Equifax, FICO, Moody’s Analytics and Oracle, each leading with unique AI-driven scoring and compliance solutions.

2. What will be the size of the Credit Risk Assessment Market in the coming years?

The Credit Risk Assessment Market size is projected to grow from USD 9.52 Bn in 2025 to USD 23.97 Bn by 2032 at a CAGR of 14.1%.

3. Which end-user industry has the largest growth opportunity?

Banking & Finance leads with over 45% of new deployments in 2024, but telecom and retail segments are expanding at 12–15% annually.

4. How will market development trends evolve over the next five years?

Expect real-time risk monitoring, explainable AI, and open banking integrations to dominate, driving faster implementation cycles and modular pricing models.

5. What is the nature of the competitive landscape and challenges in the Credit Risk Assessment Market?

Competition centers on AI accuracy, regulatory compliance and cloud versus on-premise offerings; challenges include data privacy and model interpretability.

6. What go-to-market strategies are commonly adopted in the Credit Risk Assessment Market?

Partnerships with regional banks, cloud bundling with ERP suites, acquisition of analytics startups, and outcome-based pricing models are widely used growth strategies.

About Us:

Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.

Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr Shah
Email: Send Email
Phone: 12524771362
Address:Coherent Market Insights Pvt Ltd, 533 Airport Boulevard,
City: Burlingame
State: Burlingame
Country: India
Website: https://www.coherentmarketinsights.com/industry-reports/credit-risk-assessment-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Credit Risk Assessment Market Global Rising Demand & Huge Scope Till 2032 | Coherent Market Insights

EPC Consulting Market 2025 : Industry Size to Reach USD 25.67 Billion by 2032, At a CAGR of 8.8%

“EPC Consulting Market”

Industry Overview

The EPC Consulting Market is experiencing accelerated business growth driven by large-scale infrastructure, energy transition, and digital transformation initiatives. Our proprietary market research reveals an expanding industry size underpinned by sustainability mandates and smart engineering solutions across regions. This EPC consulting market analysis underscores rising demand for integrated project delivery and technical advisory services from 2025 onward.

Market Size and Overview-

The Global EPC Consulting Market size is estimated to be valued at USD 14.22 Bn in 2025 and is expected to reach USD 25.67 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032. This market forecast is backed by robust capital expenditure in energy, infrastructure, and petrochemical sectors, reflecting sustained market growth and favorable industry trends.

Request Sample Pages: https://www.coherentmarketinsights.com/insight/request-sample/6284

Key Takeaways:

Region

• North America: Infrastructure modernization and shale gas EPC projects are boosting regional industry size.

• Latin America: Mining and oilfield development in Brazil and Mexico underpin growing EPC consulting demand.

• Europe: Green energy targets in Germany and France create fresh market opportunities for carbon-neutral EPC.

• Asia Pacific: Rapid urbanization in China and India drives multi-billion-dollar smart city and rail EPC pipelines.

• Middle East: Mega-city developments and petrochemical expansions in UAE and Saudi Arabia dominate market dynamics.

• Africa: Power generation and water management projects in South Africa and Egypt highlight untapped market scope.

Segment Covers

• Service Type:

– FEED (Front-End Engineering Design): Used in pre-FEED oil & gas projects to reduce costs by 10%.

– Detailed Engineering: Supports turnkey chemical plants, as seen in a $1.2 Bn Saudi project.

– Project Management: Employed by utilities for grid modernization in Europe.

• Application:

– Energy & Power: Solar PV and wind farm EPC consulting captured 18% of total market revenue in 2024.

– Infrastructure: High-speed rail and metro systems drove 22% year-on-year market growth in Asia Pacific.

– Petrochemicals: Integrated consulting for ethylene crackers accounted for $2 Bn of global consulting fees.

• End-User:

– Oil & Gas: Combined upstream and downstream EPC consulting grew by 9% in 2025.

– Utilities: Smart grid advisory contracts increased 30% in North America.

– Construction & Real Estate: Urban development projects leveraged BIM-enabled consulting for efficiency gains.

Growth Factors

• Digital Engineering Adoption: In 2024, 35% of global EPC consulting revenue stemmed from digital twins, driving an 8.8% CAGR.

• Sustainability Regulations: Europe’s net-zero roadmaps catalyzed green EPC consulting engagements, up 12% in the past year.

• Cross-Border Mega-Projects: Middle East awarded over $150 Billion in EPC contracts in 2024, elevating global market share for consultancies.

• Infrastructure Stimulus Packages: Asia Pacific stimulus funding exceeded $200 Bn in 2025, fueling demand for integrated EPC advisory services.

Get Customization on this Report: https://www.coherentmarketinsights.com/insight/request-customization/6284

Market Trends

• AI-Driven Optimization: By early 2025, AI in project scheduling cut delivery timelines by 15%, per several recent case studies.

• Modular Construction Integration: 40% of North American EPC consulting assignments in 2024 included prefabrication strategies.

• Digital Twin & IoT Collaboration: Real-time asset performance monitoring grew by 30% in oil & gas consulting orders.

• Cloud-Native Platforms: EPC Consulting Market trends indicate a shift toward SaaS-based engineering tools for real-time collaboration.

Actionable Insights

• Production Capacity: Leading firms expanded digital engineering headcount by 20% in 2024 to meet surging project pipelines.

• Pricing Dynamics: Average EPC consulting fees rose to $120/man-hour in Q1 2025, an 8% premium over 2024 rates.

• Export Flows: Asia Pacific consultancies exported $5 Bn in service contracts to Middle East markets in 2024.

• Use Cases: Predictive maintenance engagements in utilities soared by 25%, unlocking new EPC Consulting Market revenue streams.

• Micro-Indicators: Risk modeling projects expanded by 18% across megaprojects, improving budget forecasts by 10%.

• Nano-Size Indicators: IoT-enabled asset monitoring proofs-of-concept increased by 22% among key players in 2024, indicating rising market share.

Key Players

Wood plc

WorleyParsons

Fluor Corporation

Aecom

Jacobs

SNC-Lavalin

Hatch Ltd

Bechtel Corporation

KBR Inc

TechnipFMC

Chicago Bridge & Iron Company

Hyundai Engineering & Construction

McDermott International Inc

National Projects Construction Corporation

Galfar

Tecnicas Reunidas

Saipem

Daewoo E&C

Petrofac Ltd

Samsung Engineering

Competitive Strategies

• Jacobs’ acquisition of CH2M in 2024 elevated its integrated EPC consulting capabilities, increasing North American market share by 5%.

• Fluor Corporation partnered with leading digital twin providers in 2025 to reduce project cost overruns by 12%.

• WorleyParsons launched a cloud-based FEED platform in 2024, capturing new market opportunities across Asia Pacific and improving operational efficiency by 15%.

Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6284

FAQs

1. Who are the dominant players in the EPC Consulting Market?

Major market players include Wood plc, WorleyParsons, Fluor Corporation, Aecom, Jacobs, SNC-Lavalin, Bechtel Corporation, KBR Inc, and TechnipFMC.

2. What will be the size of the EPC Consulting Market in the coming years?

The market size is projected to grow from USD 14.22 Bn in 2025 to USD 25.67 Bn by 2032 at a CAGR of 8.8%.

3. Which end-user industry has the largest growth opportunity?

Energy & Power, particularly renewable energy projects, represent the largest market opportunity, accounting for nearly 20% of total EPC consulting market revenue in 2024.

4. How will market development trends evolve over the next five years?

Key trends include AI-driven optimization, modular construction integration, digital twin & IoT collaboration, and cloud-native engineering platforms reshaping project delivery.

5. What is the nature of the competitive landscape and challenges in the EPC Consulting Market?

Fierce competition among global engineering houses, price pressure from new entrants, and stringent environmental regulations pose ongoing market challenges. Strategic digital partnerships and M&A are common defensive tactics.

6. What go-to-market strategies are commonly adopted in the EPC Consulting Market?

Firms leverage digital transformation alliances, bundled service offerings, strategic acquisitions, and regional partnerships to enhance service scope, capture new projects, and drive business growth.

About Us:

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: EPC Consulting Market 2025 : Industry Size to Reach USD 25.67 Billion by 2032, At a CAGR of 8.8%

Obesity Clinical Trials Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Obesity Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report

Key Takeaways from the Obesity Pipeline Report

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus.
In June 2025, Zomagen Biosciences Ltd. conducted a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide.
In June 2025, Boehringer Ingelheim organized a study is to find out whether a medicine called survodutide (BI 456906) helps people living with obesity disease to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine.
In June 2025, Novo Nordisk A/S announced a study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called ‘the main study’ and the second part is called ‘the extension study’. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more likely to get CagriSema than placebo. If participants get CagriSema in the main study, participants will continue on CagriSema in the extension study.
In June 2025, Hanmi Pharmaceutical Company Limited conducted a phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus.
DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.

Discover how the Obesity treatment paradigm is evolving. Access DelveInsight’s in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies

Obesity Emerging Drugs

Survodutide: Zealand Pharma

Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.

Ecnoglutide: Sciwind Biosciences

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity.

CT-868: Carmot Therapeutics

CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868’s effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity.

DD01: D&D Pharmatech

DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).

The Obesity pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight’s expert-driven report today! @ Obesity Unmet Needs

Obesity Companies

Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Obesity Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives

Scope of the Obesity Pipeline Report

Coverage- Global
Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Obesity drug development? Find out in DelveInsight’s exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies

Table of Contents

Introduction
Executive Summary
Obesity Overview
Obesity Pipeline Therapeutics
Obesity Therapeutic Assessment
Late Stage Products (Phase III)
Survodutide: Zealand Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CT-868: Carmot Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DD01: D&D Pharmatech
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Obesity Products
Obesity Key Companies
Obesity Key Products
Obesity Unmet Needs
Obesity Market Drivers
Obesity Market Barriers
Obesity Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Clinical Trials Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Oncology Information System Market to Reach USD 4.80 Billion by 2030 at a CAGR of 8.5%, Driven by Growing Digital Health Adoption and Rising Cancer Burden

“Oncology Information System Market”

Mordor Intelligence has published a new report on the Oncology Information System Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

Mordor Intelligence, in its latest oncology information system market report, forecasts that the global oncology information system market will grow significantly, reaching an estimated USD 4.80 billion by 2030 from USD 3.20 billion by 2025. The oncology information system (OIS) market is gaining importance as healthcare providers seek more efficient, accurate, and integrated methods to manage cancer care. These systems are designed to capture, store, and manage patient-specific cancer treatment information, covering aspects such as diagnosis, planning, scheduling, treatment, and follow-up. OIS solutions play a critical role in improving clinical workflows, reducing medical errors, and supporting multidisciplinary teams involved in cancer care.

Key Trends

The oncology information system (OIS) market is experiencing steady expansion thanks to several notable trends:

1. Rising Cancer Incidence and Cancer Care Needs Global cancer cases surged to around 18 million new diagnoses in 2020, escalating the urgency for systems capable of comprehensive patient data management throughout the care continuum.

2. Government Initiatives and Funding Support Increased investment by governments and research institutions, such as the USD 7.3 billion allocation to the National Cancer Institute (including USD 216 million for Cancer Moonshot), supports enhanced patient data capture and improved cancer care infrastructure.

3. Digital Health Technologies Driving OIS Adoption Healthcare facilities are integrating advanced OIS software such as patient information systems and treatment planning tools with AI and ML capabilities to streamline workflows, cut errors, and foster data driven decision making.

4.Post‑Pandemic Recovery Projecting Renewed Growth While OIS implementation slowed during the COVID‑19 surge, the market has bounced back, with delayed implementations resuming and contributing to renewed growth momentum.

5. Regional Adoption Led by North America North America held over 42% market share in 2022 driven by robust healthcare IT systems and favorable policies with significant investments from Asia-Pacific and other regions further boosting adoption.

Market Segmentation

The oncology information system market breakdown spans products, applications, and end users:

By Oncology

The market is categorized into two primary offerings:

Software: Constituting approximately 83% of the market in 2022. This includes:

Patient Information Systems: Crucial for medical history, treatment documentation, and care coordination.

Treatment Planning Systems: Tailored radiation and medical oncology planning.

Services: Providing implementation support, training, and ongoing maintenance

By Application

Systems are deployed across different oncology domains

Medical Oncology: Medical Oncology focuses on the treatment of cancer using systemic therapies such as chemotherapy, immunotherapy, hormone therapy, and targeted therapy. Medical oncologists manage patient care before, during, and after treatment, often in collaboration with other oncology specialists. In an OIS, medical oncology modules help in documenting drug regimens, scheduling cycles, tracking side effects, and maintaining treatment histories to ensure continuity and safety in care.

Surgical Oncology: Surgical oncology involves the diagnosis, staging, and removal of tumors through surgical intervention. It plays a critical role in cancer treatment, especially when physical removal of the tumor is essential. Within an oncology information system, surgical oncology workflows include surgical planning, integration with imaging and pathology reports, and post-operative monitoring. These tools support better clinical decision-making and enhance coordination among care teams.

Radiation Oncology: Radiation oncology uses high-energy radiation to destroy cancer cells or shrink tumors. It includes external beam radiation therapy and brachytherapy, among others. OIS platforms designed for radiation oncology often integrate treatment planning systems, simulate sessions, track dosage administration, and manage imaging data. This ensures accuracy in treatment delivery and supports compliance with safety protocols and quality assurance standards.

By End User

The primary consumers of OIS are:

Hospitals: Hospitals are the largest users of oncology information systems, often managing high volumes of cancer patients across various departments. These facilities require robust, integrated OIS platforms to coordinate care among radiation oncology, medical oncology, surgical teams, and diagnostic units. OIS helps hospitals streamline workflows, centralize patient records, monitor treatment outcomes, and comply with regulatory standards, all while supporting multidisciplinary cancer care.

Oncology Clinics: Oncology clinics specialize in the diagnosis and treatment of cancer and often provide outpatient services. These clinics rely on OIS solutions to manage scheduling, chemotherapy administration, follow-ups, and patient education. Given their focused approach to cancer care, clinics benefit from systems that offer tailored oncology modules, improve operational efficiency, and enhance communication between specialists and patients.

Research & Academic Centers: Research and academic institutions use oncology information systems primarily for clinical research, data analysis, and medical education. These centers benefit from advanced data capture features, integration with clinical trial systems, and tools for outcome tracking and reporting. OIS platforms in these settings support evidence-based practices, facilitate longitudinal studies, and help train the next generation of oncology professionals.

By Geography

Europe: Europe holds a significant portion of the market, propelled by investments in healthcare modernization, cancer care initiatives, and requirements for interoperability. Countries such as Germany, France, Italy, Spain, and the UK are at the forefront of adopting oncology information systems to streamline patient data management, integrate radiotherapy planning, and support value-based care frameworks.

Asia-Pacific: The Asia-Pacific region is the fastest growing segment in the OIS market, with an estimated CAGR of 9.85% between 2025 and 2030. Expansion reflects a surge in healthcare infrastructure development, increased digital transformation efforts, and growing cancer incidence. Markets such as China, Japan, India, South Korea, and Australia are accelerating adoption via cloud-based OIS deployments and national cancer care strategies.

Middle East & Africa: Middle East and Africa, including the Gulf Cooperation Council (GCC) countries and South Africa, are seeing gradual yet steady growth. Healthcare systems are increasingly investing in oncology IT as part of broader cancer control and digital health initiatives. While adoption lags behind North America and Europe, the region is expected to gain traction as government and private-sector support expands.

South America: South America’s OIS market is progressing steadily, driven by growing cancer care infrastructure and digitization efforts in healthcare institutions across Brazil, Argentina, and neighboring countries. As hospitals and specialty clinics invest in digital platforms, oncology information systems are becoming instrumental in standardizing patient records, treatment planning, and data reporting.

Key Players

The OIS market features several established and emerging companies:

Oracle: Delivers integrated oncology modules as part of its comprehensive healthcare IT suite.

Siemens Healthineers: Offers robust radiotherapy planning solutions and clinical data systems.

Elekta: Specializes in radiation oncology software, including precision treatment planning.

Koninklijke Philips N.V: recognized as a leading provider in the oncology information system market. The company offers a range of software modules and clinical workflows that integrate cancer care management.

McKesson Corporation: Mckesson Corporation also ranks among the major players in the global oncology information system sector. The company’s platforms are built to manage chemotherapy workflows, medication tracking, and clinical data exchange

Conclusion

The global oncology information system market is poised for strong growth, projecting from USD 3.20 billion in 2025 to USD 4.80 billion by 2030, riding an annual growth rate of around 8.5%.

This expansion is driven by several converging forces: rising cancer cases, supportive policy frameworks, digital innovation in healthcare, and enhanced implementation pace post COVID. North America leads adoption, but Asia-Pacific and other regions are closing thanks to infrastructure improvements and heightened digital health investments.

Looking ahead, as software platforms integrate AI, machine learning, and data analytics, and as service models evolve to meet diverse institutional needs, OIS will become even more central to oncology care delivery, enabling better workflow coordination, patient outcomes, and cost efficiencies. The competitive landscape is vibrant, with both established players and new entrants contributing to ecosystem development through strategic mergers and partnerships.

In summary, the oncology information system market is entering a mature growth phase. Its capacity to respond to pressing clinical and administrative demands, combined with sustained R&D and funding initiatives, ensures that healthcare providers worldwide will continue to invest in these platforms transforming cancer care across the globe.

Industry Related Reports

Oncology Based In-Vivo CRO Market: The Global Oncology-Based In-Vivo Contract Research Organization (CRO) Market report is segmented by Indication (Blood Cancer, Solid Tumors, and Other Indications), Model (Syngeneic, Xenograft, and Patient-Derived Xenograft (PDX)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the market value (in USD million) for all the above segments.

Oncology Clinical Trials Market: The Oncology Clinical Trials Market report is segmented by Phase (Phase I, Phase II, Phase III, Phase IV), Design (Treatment Studies and Observational Studies), Cancer Type (Lung Cancer, Breast Cancer, and Others), Therapeutic Modality (Immunotherapy and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides market forecasts in terms of value (USD).

For More Insights: https://www.mordorintelligence.com/industry-reports/oncology-clinical-trials-market?utm_source=abnewswire

Precision Oncology Market: The Precision Oncology Market report is segmented by Type (Therapeutics and Diagnostics), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Other Cancer Types), End-User (Hospitals, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Research & Academic Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:media@mordorintelligence.com https://www.mordorintelligence.com/

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email: Send Email
Phone: +1 617-765-2493
Address:5th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oncology Information System Market to Reach USD 4.80 Billion by 2030 at a CAGR of 8.5%, Driven by Growing Digital Health Adoption and Rising Cancer Burden

Fintech as a Service Market Future Scope: Size, Share, Trends, Opportunities Analysis Forecast Report By 2029

“PayPal (US), Mastercard (US), Fiserv (US), Block (US), Rapyd (UK), Envestnet (US), Upstart (US), Solid Financial (US), FIS (US), Synctera (US), Stripe (US) , Adyen (Netherlands), Dwolla (US), Finastra (UK), Revolut (UK), Fispan (Canada), Nium (Singapore), Airwallex (Australia), Sofi Technologies Inc. (US).”

Fintech as a Service (FaaS) Market Size Share, Growth Analysis by Type (Banking, Payment, Insurance, Investment), Technology (AI, Blockchain, RPA, API), Application, End User and Region – Global Industry Forecast to 2029.

The Fintech as a Service (FaaS) market is projected to expand at a Compound Annual Growth Rate (CAGR) of 17.6% from USD 358.8 billion in 2024 to USD 806.9 billion by 2029. Digital transformation, regulatory changes, and the need for creative financial solutions are driving the FaaS market’s expansion.

Financial services that are formed, offered, and mobilized with a strong focus on customer security, data privacy, financial inclusion, and social ethics are being encouraged by the Fintech market. The market tends to focus on creating solutions while upholding strict rules of accountability, openness, and fairness that show that these financial services are not only accessible and advantageous for all, but also safe.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=9388805

FaaS solutions enable organizations to access pre-built financial technology solutions that can be integrated into existing systems, enabling businesses to provide innovative financial services, reducing the cost of new in-house development technology and the investment needed for resources, which makes it cost-efficient financial services, making high-tech tools available without a high upfront cost. With FaaS, companies can focus on competition and innovation with their core operations, delivering cutting-edge financial services to their customers.

Based on the type, Payments in the FaaS market accounts for the highest market size during the forecast period.

Payments are expected to maintain the highest market share in the FaaS market for various reasons. Their ubiquitous nature, being important to daily transactions and serving a vast customer base involving individuals, businesses, and governments, and rapid technological advancements like digital wallets, biometric authentication, upgraded security on real-time payments, convenience, and efficiency play a crucial role in financial inclusion by providing services through mobile payments in the emerging market. It acts as a boon by providing solutions and services to a major segment of the population through digital platforms. It is enhancing the customer experience by integrating payment methods to various platforms such as e-commerce, ride-sharing, and digital commerce, driving the popularity of subscription-based models, and its regulatory evolution, such as open banking payments and Payment Services Directive 2 (PSD2), creating strong authentication and open API’s.

By application, KYC Verification segment will grow at the highest CAGR during the forecasted period.

The Know Your Customer (KYC) verification segment is growing faster than any other part of the fintech-as-a-service market. This growth comes from a few key factors. Companies need to follow stricter rules, like those against money laundering and funding terrorism, as well as laws about data privacy, such as GDPR and CCPA. More cases of identity theft and financial scams make it crucial to have accurate and reliable KYC to keep customers safe.

KYC also helps make signing up new customers online smoother and quicker, improving their first experience and letting companies assess risk better. As the fintech world grows and technology improves, like fingerprint scans and smart computer analysis, the need for solid KYC checks increases. This builds customer trust and protects the good name of financial companies.

By region, Asia Pacific will grow at the highest CAGR during the forecast period.

Asia Pacific is forecasted to grow at the highest CAGR due to the rapid adoption of digitization, rising internet penetration, and widespread use of smartphones in countries like India, China, and Indonesia, which have a large customer base. These regions are one of the largest populations, which provides an opportunity for fintech companies for financial inclusion. The government’s support and praise for fintech solutions is being heavily backed up, showing a positive future aspect of growth in the FaaS market. The region also attracts a large number of investment interests from various sources due to its population and growing demand for digital financial services, mostly among middle-class earning entities. The market is also a rising hub of digital platforms, which further enhances the strong entrepreneurial ecosystem and the fintech landscape.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=9388805

Unique Features in the Fintech as a Service Market

The Fintech as a Service market is distinguished by its modular design, enabling businesses to adopt and scale individual financial functionalities such as payments, lending, KYC, or compliance independently. This flexibility allows startups and enterprises to integrate only what they need, reducing time-to-market and operational complexity.

A key characteristic of FaaS is its API-first approach, which facilitates seamless integration with existing digital ecosystems. This interoperability enables banks, e-commerce platforms, and other non-financial companies to embed financial services directly into their platforms without overhauling legacy systems.

FaaS enables broader access to financial tools for underserved markets. By offering cloud-based financial services at a lower cost and with minimal infrastructure, FaaS supports financial inclusion for SMEs, gig workers, and individuals in developing regions.

Compliance-as-a-service is a unique layer within the FaaS landscape. Providers often offer built-in support for AML, KYC, PSD2, and GDPR regulations, making it easier for clients to operate across borders while minimizing regulatory risks.

FaaS allows businesses to launch new financial products quickly by outsourcing complex backend operations such as fraud detection, transaction monitoring, and credit scoring. This agility fosters innovation and accelerates go-to-market strategies.

Major Highlights of the Fintech as a Service Market

The Fintech as a Service market is witnessing rapid expansion due to rising demand from both financial institutions and non-financial enterprises aiming to offer embedded financial solutions. Increased digital transformation initiatives and the need for cost-effective financial operations are key drivers fueling this growth globally.

One of the most prominent trends is the surge in embedded finance, where retailers, marketplaces, and SaaS providers integrate FaaS solutions to offer services like BNPL, micro-lending, or digital wallets. This trend is transforming customer engagement and expanding revenue models across industries.

Small and medium-sized enterprises are increasingly adopting FaaS platforms to access sophisticated financial infrastructure without heavy capital investment. This democratization is enabling them to compete with larger players and innovate faster in financial service delivery.

The market is marked by increasing strategic alliances among banks, fintech startups, and technology vendors. These collaborations are essential to co-develop robust FaaS ecosystems and deliver end-to-end solutions tailored to specific business needs.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=9388805

Top Companies in the Fintech as a Service Market

PayPal (US), Mastercard (US), Fiserv (US), Block (US), Rapyd (UK), Envestnet (US), Upstart (US), Solid Financial (US), FIS (US), Synctera (US), Stripe (US) , Adyen (Netherlands), Dwolla (US), Finastra (UK), Revolut (UK), Fispan (Canada), Nium (Singapore), Airwallex (Australia), Sofi Technologies Inc. (US), Margeta (US), Finx (US), Synapse (US).

PayPal (US)

PayPal (US) has a stronghold in FaaS due to its diversified offerings in payment management in the FaaS market. Paypal provides online secure payments, money transfers, and digital wallets, which are preferred by buyers and sellers. With the acquisitions of Honey Science Corporation and investments in MercadoLibre and Uber, PayPal has increased its strategic growth. These strategic partnerships, continuous investments in technologies, and adaptability to evolving market dynamics make the customer bases loyal, providing them with user-friendly services. Paypal’s growth in the FaaS market is fueled as the result of its growing initiatives in fintech as a service market with advanced technology adoption to comprehensive payment solutions and its global reach of customers.

Mastercard (US)

Mastercard partnering with the top digital payment and neobank fintechs listed by CNBC. The company provides solutions, including Mastercard Smart Data. Mastercard’s relationships with fintech companies are strategic in nature, as they can access its payment network and services. Leader in finance Mastercard allows API-first tech companies to provide more financial services efficiently. Mastercard uses technology to provide digital payments and loans to its customers. Leadership fueled by regular investments in new tech like blockchain, AI, and cloud computing and acquire companies like Baffin Bay Networks. Mastercard’s global scale, supportive regulatory framework, and agility in responding to changing customer demands with frictionless, tailored financial solutions. The Mastercard For Fintechs Program equips fintechs with the tools, insights, and network necessary to build a safe and more resilient world.

Fiserv (US)

Fiserv (US) is a leading provider in the Fintech as a Service (FaaS) market, delivering innovative payment processing, digital banking, and financial technology solutions. Its platform empowers businesses to streamline transactions, enhance customer experiences, and leverage advanced analytics for financial decision-making.

Block (US)

Block (US), formerly Square, is a leading player in the Fintech as a Service (FaaS) market, providing innovative financial solutions such as payment processing, point-of-sale systems, and business management tools. Its ecosystem empowers businesses of all sizes to streamline transactions and enhance financial operations.

Rapyd (UK)

Rapyd (UK) is a leading player in the Fintech as a Service (FaaS) market, providing a global platform that integrates payments, banking, and financial services. Its solutions enable businesses to accept payments, disburse funds, and manage financial operations seamlessly across multiple countries.esx

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/fintech-as-a-service-market-9388805.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fintech as a Service Market Future Scope: Size, Share, Trends, Opportunities Analysis Forecast Report By 2029